# US 2026/0218289 A1 · Alpha-hemolysin variants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218289 A1
- Document ID: US20260218289A1
- Status: Published application
- Kind: A1
- Application number: 19/259,376
- Filed: 2025-07-03
- Published: 2026-07-30
- Earliest claimed: 2016-04-21
- Assignees: Roche Sequencing Solutions, Inc.
- Applicants: Roche Sequencing Solutions, Inc.
- Inventors: Timothy K. CRAIG; Mark R. AMBROSO; Corissa J. HARRIS; Matthew M. DIPIETRO; Yaozhong ZOU; Marshall W. PORTER
- Web page: https://patentgrep.com/patent/US20260218289A1

## CPC

- C12Q 1/6869: Methods for sequencing
- C07K 14/31: from Staphylococcus (G)
- C12Q 1/689: for bacteria
- G01N 27/44791: {Microapparatus (sample containers with integrated microfluidic structures B01L3/5027)}
- G01N 33/48721: {Investigating individual macromolecules, e.g. by translocation through nanopores (Coulter counters in general G01N15/12; fabrication methods for nanoscale apertures B81B1/00; sequencing of nucleic acids C12Q1/68)}
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2333/31: from Staphylococcus (G)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein are variants of alpha-hemolysin having at least one mutation, such as a mutation to a positive charge. In certain examples, the mutation is selected from V149K, E287R, H35G, T109K, P151K, K147N, E111N, M113A, or combinations thereof in the mature, wild-type alpha-hemolysin amino acid sequence. The α-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having a decreased time-to-thread. The decreased time-to-thread, for example, increases DNA sequencing efficiency and accuracy.

## Claims

### Claim 1

A system for sequencing a nucleic acid comprising:
a heptameric nanopore assembly comprising an alpha-hemolysin variant, wherein the variant comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 14 and wherein the amino acid sequence of the variant comprises a positively charged amino acid substituted for one or more positions of SEQ ID NO: 14 selected from the group consisting of T109, V149, P151, and E287 of SEQ ID NO: 14;
a chip comprising a plurality of sensing electrodes and a membrane that is disposed adjacent or in proximity to one or more of the sensing electrodes; and
a set of negatively charged tagged nucleotides.

### Claim 2

A method for sequencing a target nucleic acid sequence, comprising:
providing a chip, the chip comprising a plurality of sensing electrodes and a membrane that is disposed adjacent or in proximity to the sensing electrodes;
disposing, within the membrane, a heptameric nanopore assembly, the heptameric nanopore assembly comprising seven alpha-hemolysin subunits arranged in a nanopore, wherein (i) at least one of the seven alpha-hemolysin subunits comprises an α-hemolysin variant and a DNA polymerase covalently attached to one of the seven alpha-hemolysin subunits, wherein (ii) the variant comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 14, and wherein (iii) the amino acid sequence of the variant comprises a positively charged amino acid substituted for one or more positions of SEQ ID NO: 14 selected from the group consisting of T109, V149, P151, and E287 of SEQ ID NO: 14;
contacting the chip with a target nucleic acid sequence and a plurality of negatively charged tagged nucleotides;
applying a voltage across the membrane;
determining, by one or more of the sensing electrodes, one or more current changes associated with the heptameric nanopore assembly; and
determining, with the aid of a computer processor and based on the one or more of the determined current changes associated with the heptameric nanopore assembly, a sequence for the target nucleic acid sequence.

### Claim 3

An α-hemolysin variant comprising an amino acid sequence selected from the group consisting of:
(a) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 5, with the proviso that said amino acid sequence comprises:
(a1) a glycine residue at a position corresponding to position 35 of SEQ ID NO: 5;
(a2) an alanine residue at a position corresponding to position 144 of SEQ ID NO: 5;
(a3) a lysine residue at a position corresponding to position 149 of SEQ ID NO: 5; and
(a4) an arginine residue at a position corresponding to position 287 of SEQ ID NO: 5;
(b) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 6, with the proviso that said amino acid sequence comprises:
(b1) a lysine residue at a position corresponding to position 149 of SEQ ID NO: 6; and
(b2) an arginine residue at a position corresponding to position 287 of SEQ ID NO: 6;
(c) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 7, with the proviso that said amino acid sequence comprises:
(c1) a glycine residue at a position corresponding to position 35 of SEQ ID NO: 7; and
(c2) a lysine residue at a position corresponding to position 109 of SEQ ID NO: 7;
(d) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 8, with the proviso that said amino acid sequence comprises:
(d1) a glycine residue at a position corresponding to position 35 of SEQ ID NO: 8; and
(d2) a lysine residue at a position corresponding to position 151 of SEQ ID NO: 8;
(e) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 9, with the proviso that said amino acid sequence comprises:
(e1) a glycine residue at a position corresponding to position 35 of SEQ ID NO: 9;
(e2) a lysine residue at a position corresponding to position 149 of SEQ ID NO: 9; and
(e3) a lysine residue at a position corresponding to position 151 of SEQ ID NO: 9;
(f) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10, with the proviso that said amino acid sequence comprises:
(f1) a glycine residue at a position corresponding to position 35 of SEQ ID NO: 10;
(f2) a lysine residue at a position corresponding to position 109 of SEQ ID NO: 10; and
(f3) a lysine residue at a position corresponding to position 149 of SEQ ID NO: 10;
(g) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 11, with the proviso that said amino acid sequence comprises:
(g1) a glycine residue at a position corresponding to position 35 of SEQ ID NO: 11;
(g2) an asparagine residue at a position corresponding to position 111 of SEQ ID NO: 11;
(g3) an alanine residue at a position corresponding to position 113 of SEQ ID NO: 11;
(g4) a glycine residue at a position corresponding to position 126 of SEQ ID NO: 11;
(g5) a glycine residue at a position corresponding to position 127 of SEQ ID NO: 11;
(g6) a glycine residue at a position corresponding to position 128 of SEQ ID NO: 11;
(g7) a glycine residue at a position corresponding to position 129 of SEQ ID NO: 11;
(g8) a glycine residue at a position corresponding to position 130 of SEQ ID NO: 11;
(g9) a glycine residue at a position corresponding to position 131 of SEQ ID NO: 11;
(g10) an asparagine residue at a position corresponding to position 147 of SEQ ID NO: 11; and
(g11) a lysine residue at a position corresponding to position 149 of SEQ ID NO: 11;
(h) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 12, with the proviso that said amino acid sequence comprises:
(h1) an asparagine residue at a position corresponding to position 111 of SEQ ID NO: 11;
(h2) an alanine residue at a position corresponding to position 113 of SEQ ID NO: 12;
(h3) a glycine residue at a position corresponding to position 126 of SEQ ID NO: 12;
(h4) a glycine residue at a position corresponding to position 127 of SEQ ID NO: 12;
(h5) a glycine residue at a position corresponding to position 128 of SEQ ID NO: 12;
(h6) a glycine residue at a position corresponding to position 129 of SEQ ID NO: 12;
(h7) a glycine residue at a position corresponding to position 130 of SEQ ID NO: 12;
(h8) a glycine residue at a position corresponding to position 131 of SEQ ID NO: 12;
(h9) an asparagine residue at a position corresponding to position 147 of SEQ ID NO: 12; and
(h10) a lysine residue at a position corresponding to position 149 of SEQ ID NO: 12; and
(i) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 13, with the proviso that said amino acid sequence comprises:
(i1) a glycine residue at a position corresponding to position 35 of SEQ ID NO: 13;
(i2) a lysine residue at a position corresponding to position 109 of SEQ ID NO: 13;
(i3) a lysine residue at a position corresponding to position 149 of SEQ ID NO: 13; and
(i4) a lysine residue at a position corresponding to position 151 of SEQ ID NO: 13.

### Claim 4 (depends on 3)

The α-hemolysin variant of claim 3, wherein the at least 80% sequence identity is a sequence identity according to CLUSTAL-W program in MacVector version 13.0.7, operated with an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM 30 similarity matrix.

### Claim 5 (depends on 3)

A heptameric nanopore assembly comprising seven alpha-hemolysin subunits arranged in a nanopore, wherein at least one of the seven alpha-hemolysin subunits comprises the α-hemolysin variant of claim 3 and a DNA polymerase covalently attached to one of the seven alpha-hemolysin subunits.

### Claim 6 (depends on 5)

The heptameric nanopore assembly of claim 5, wherein the nanopore has a decreased time to thread (TTT) relative to a heptameric nanopore assembly consisting of native alpha-hemolysins.

### Claim 7 (depends on 5)

The heptameric nanopore assembly of claim 5, wherein the nanopore has at least a 10% decreased TTT relative to the heptameric nanopore assembly including native alpha-hemolysins.

### Claim 8 (depends on 5)

The heptameric nanopore assembly of claim 5, wherein the nanopore has at least a 50% decreased TTT relative to the heptameric nanopore assembly including native alpha-hemolysins.

### Claim 9 (depends on 5)

The heptameric nanopore assembly of claim 5, wherein the nanopore has at least a 80% decreased TTT relative to the heptameric nanopore assembly including native alpha-hemolysins.

### Claim 10 (depends on 5)

A system for sequencing a nucleic acid comprising:
the heptameric nanopore assembly according to claim 5;
a chip comprising a plurality of sensing electrodes and a membrane that is disposed adjacent or in proximity to one or more of the sensing electrodes; and
a set of negatively charged tagged nucleotides.

### Claim 11 (depends on 5)

A method for sequencing a target nucleic acid sequence, comprising:
providing a chip, the chip comprising a plurality of sensing electrodes and a membrane that is disposed adjacent or in proximity to the sensing electrodes;
disposing, within the membrane, the heptameric nanopore assembly of claim 5;
contacting the chip with a target nucleic acid sequence and a plurality of negatively charged tagged nucleotides;
applying a voltage across the membrane;
determining, by one or more of the sensing electrodes, one or more current changes associated with the heptameric nanopore assembly; and
determining, with the aid of a computer processor and based on the one or more of the determined current changes associated with the heptameric nanopore assembly, a sequence for the target nucleic acid sequence.
